What is Soligenix?
Soligenix is a clinical-stage biopharmaceutical firm dedicated to addressing serious inflammatory diseases with unmet medical needs. The company is also advancing a portfolio of biodefense vaccines and therapeutics, positioning itself at the intersection of public health and advanced medical solutions. The recent enterprise-level funding suggests a strategic pivot or expansion phase for the company.
How much funding has Soligenix raised?
Soligenix has raised a total of $35M across 4 funding rounds:
Stock Offering
$7.1M
Debt
$350K
Debt
$20M
Stock/Share Issuance
$7.5M
Stock Issuance/Offering (2013): $7.1M, investors not publicly disclosed
Debt (2020): $350K led by PPP
Debt (2020): $20M supported by Pontifax Medison Debt Financing
Stock/Share Issuance (2025): $7.5M, investors not publicly disclosed
What's next for Soligenix?
With the recent major strategic investment, Soligenix is poised to accelerate its clinical development programs and potentially broaden its biodefense offerings. This capital infusion is expected to fuel further research and development, aiming to bring novel treatments and preventative measures to market. The company's focus on critical health areas indicates a trajectory towards significant market impact and potential for future growth.
See full Soligenix company page
